Heaton Named Fellow by American Pharmacists Association
Pam Heaton, PhD, is to be recognized with the distinction of fellow at the American Pharmacists Association (APhA) 2018 Awards and Honors Program March 16-19 in Nashville, Tennessee.
The APhA awards and honors program is the most comprehensive recognition program in the profession of pharmacy. Fellows are either members of the APhA Academy of Pharmacy Practice and Management or the APhA Academy of Pharmaceutical Research and Science with a minimum of 10 years professional experience. To become a fellow, members must have demonstrated exemplary professional achievements and service to the profession through activities with APhA and other national, state or local professional organizations.
Heaton is chair and professor of pharmacy practice and administrative sciences at the James L. Winkle College of Pharmacy. She teaches a required pharmacy ethics course in the doctor of pharmacy curriculum. She also trains graduate students in the area of health outcomes. Her current research focus is on the use of secondary databases to evaluate clinical, humanistic and economic outcomes of drug therapy. She has published over 60 manuscripts and given over 100 poster presentations.
In partnership with Kroger Pharmacy, Heaton has developed a two-year MS/residency with an emphasis in community pharmacy. Also, with Kroger Pharmacy, along with the Cincinnati Health Council, Health Bridge and several hospitals, Heaton received a grant from National Association of Chain Drug Stores to determine whether community pharmacists can reduce 30-day readmissions for patients with priority conditions.
She is an associate editor for the Journal of the American Pharmacists Association and led the development of its first community residency issue.
Tags
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.